The serum SP-A is a prognostic factor, while serial serum KL-6 levels are also used to monitor response to the therapy in PM/DM-ILD in patients [26]. Suzuki et al. described their retrospective experience (1985-2007) with five PM/DM/amyopathic dermatomyositis (AMD) patients (one PM, four ADM with one positive for anti-Jo-antibody, three females, two males) with severe resistant to treat ILD with similar clinical courses, parameters, and demography. The gene discussed is MUC1; the disease is interstitial lung disease.